Faculty Disclosures

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

Last Name	Role in Activity	Commercial Interest	Nature of Relevant Financial Relationship	
			What Was Received	For What Role
Bajorin	Speaker	• Dragonfly, Fidia Pharma USA Inc., Merck & Co., Sharp & Dohme, • Bristol-Myers Squibb, Merck & Co.	• Honorarium • Research Grants	• Consultant • Principle Investigator
Calais	Speaker	• Advanced Accelerator Applications, Blue Earth Diagnostics Limited, Curium SAS, GE Healthcare Janssen Pharmaceuticals, Progenics Pharmaceuticals • Progenics Pharmaceuticals • Telix Pharmaceuticals	• Honorarium • Research Grants • Honorarium	• Consultant • Principle Investigator • Speaker
Gandara	Speaker	• None	• N/A	• N/A
Gertz	Speaker	• AbbVie Inc., Bristol-Myers Squibb/Celgene • Akcea Therapeutics, Alnylam Pharmaceuticals, Ambry Genetics, Amgen, Bristol-Myers Squibb/Celgene, Janssen Pharmaceuticals, Karyopharm Therapeutics, Prothena Corporation, Research to Practice, Sanofi • Ionis Pharmaceuticals • Pfizer • i3 Health • Aurora Biopharma	• Honorarium • Honorarium • Honorarium • Research Grants • Honorarium • Stock Options	• Data and Safety Monitoring Board • Consultant • Advisory Board • Investigator • Speaker • Advisory Board
Kantarjian	Speaker	• AbbVie Inc., Amgen, Bristol-Myers Squibb, Daiichi Sankyo, ImmunoGen, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi • Actinium Pharmaceuticals • AbbVie Inc., Adaptive Biotechnologies, Amgen, Aptitude Health, Bio Ascend, Daiichi Sankyo, Delta Fly Pharma, Inc., Janssen Global, Novartis, Oxford Biomedical, Pfizer, Takeda	• Research Grants • Honorarium • Honorarium	• Research Support • Advisory Board • Consultant/Speaker
Kelton	Speaker	• None	• N/A	• N/A
Klempner	Speaker	• Bristol-Myers Squibb, Eli Lilly, Merck & Co., Pieris Pharmaceuticals • Signatera, Inc.	• Honorarium • Honorarium	• Advisory Board • Consultant
Kosty	Course Director, Moderator	• Amgen, EMD Serono Inc., Genentech, Merck & Co. • Biocept Inc.	• Grants • Consulting Fees	• Research Support • Consultant

Little	Speaker	• Bluebird Bio, Global Blood Therapeutics	• Research Support	• Principle Investigator
Ma	Speaker	• Takeda • Takeda	• Honorarium • Research Support	• Consultant • Safety Study
Mato	Speaker	• AbbVie Inc., Aprea, AstraZeneca, DTRM, Genentech, Johnson & Johnson, GenMAB, LOXO, Octopharma, Pharmacyclics, TG Therapeutics, Inc • AbbVie Inc., Aprea, AstraZeneca, DTRM, Genentech, Johnson & Johnson, GenMAB, LOXO, Octopharma, Pharmacyclics, TG Therapeutics, Inc	• Honorarium • Research Support	• Consultant • Research
McArthur	Speaker	• AstraZeneca, Daiichi-Sankyo, Eli Lilly, Merck & Co., Seattle Genetics	• Honorarium/Travel Expenses	• Advisory Board
Mehnert	Speaker	• Amgen, EMD Serono Inc., Merck, Sharp & Dohme, Pfizer • Array BioPharma, Bristol-Myers Squibb, EMD Serono Inc., Sanofi/Regeneron • Amgen, AstraZeneca, Bristol-Myers Squibb, EMD Serono, Immunocore, Incyte, Macrogenics, Merck, Novartis, Polynoma, Sanofi, Sharp & Dohme	• Honorarium • Honorarium • Research Grant	• Consultant • Advisory Board • Research
Moeller	Peer Reviewer	• None	• N/A	• N/A
Moll	Speaker	• None	• N/A	• N/A
Nastoupil	Speaker	• Bristol-Myers Squibb/Celgene, Genentech, Janssen, Novartis, TG Therapeutics • Bayer, Bristol-Myers Squibb/Celgene, Genentech, Gilead/Kite, Janssen, Novartis, TG Therapeutics	• Research Support • Honorarium	• Principle Investigator • Advisory Board
Ortel	Speaker	• Instrumentation Laboratory, Stago, Siemens • Instrumentation Laboratory • Up-To-Date	• Research Funding • Honorarium • Royalties	• Research • Consultant • Chapter Preparation/Review
Pal	Speaker	• None	• N/A	• N/A
Pierce	Speaker	• None	• N/A	• N/A
Ramalingam	Speaker	• AbbVie Inc., Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Merck, Takeda • Advaxis, Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, Takeda, Tesaro	• Honorarium • Research Grant	• Consultant • Research
Sherman	Speaker	• Eisai	• Honorarium	• Consultant
Singh	Speaker	• Daiichi Sankyo, Deciphera, Eisai • Expert Perspectives, OncLive • Eli Lilly, Novartis • Blueprints, Eli Lilly, Roche • Eli Lilly, Blueprints, Deciphera, Nanocarrier • Certis Oncology Solutions	• Honorarium • Honorarium • Honorarium • Honorarium • Research Support • Stock Options	• Consultant • Speaker • Speakers Bureau • Advisory Board • Clinical Trail • Board of Directors

Tripathy	Speaker	• AstraZeneca, Genomic Health, Immunomedica, OncoPep, Pfizer • Novartis	• Honorarium • Research Grant	• Consultant • Research
Wang	Speaker	• Acerta Pharma/AstraZeneca, BeiGene, BioInvent, Bristol-Myers Squibb/Celgene, Eli Lilly, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Loxo Oncology, Molecular Templates, VelosBio, Verastem, • AstraZeneca, Bristol-Myers Squibb/Celgene, Guidepoint Global, InnoCare, Janssen, Juno, Loxo, Kite Pharma, MORE Health, Nobel Insight, Oncternal, Pharmacyclics, Pulse Biosciences • AstraZeneca, Beijing Medical Award Foundation, Dava Oncology, Janssen, Lu Daopei Medical Group, OMI, Pharmacyclics, Targeted Oncology	• Grant Funding • Honorarium • Honorarium/Travel Expenses	• Principle Investigator • Consultant • Speaker
Warkentin	Speaker	• Informa (Taylor & Francis) • Aspen Global, Instrumentation Laboratory, Law Firms Octapharma	• Royalties • Honorarium	• Book Editor on HIT • Consultant
Zelenetz	Speaker	• Adaptive Biotech, Amgen, Bristol-Myers Squibb/Celgene, Genentech/Roche, Gilead, Janssen, Novartis • AbbVie, Inc., AstraZeneca, Genentech, Gilead, MorphoSys, • BeiGene, Gilead, MEI Pharma Roche • BeiGene • Bristol-Myers Squibb, Celgene, Juno	• Honorarium • Honorarium • Research Grants • Honorarium • Honorarium	• Consultant • Advisory Board • Research • DMC Chair • DMC Member
CME Committee	CME approval, all final decision-making on courses	• None	• N/A	• N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile activity	• None	• N/A	• N/A

Glossary of Terms

Commercial Interest

The ACCME defines a "commercial interest" as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

Financial Relationships

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers' bureau, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Conflict of Interest

The ACCME considers financial relationships to create actual conflicts of interest in CME when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME considers "content of CME about the products or services of that commercial interest" to include content about specific agents/devices, but not necessarily about the class of agents/devices, and not necessarily content about the whole disease class in which those agents/devices are used. With respect to financial relationships with commercial interests, when a person divests themselves of a relationship it is immediately not relevant to conflicts of interest but it must be disclosed to the learners for 12 months.